Heartflow (NASDAQ:HTFL) Stock: Insider Campbell Rogers Sells 12,156 Shares

Heartflow, Inc. (NASDAQ:HTFL – Get Free Report) insider Campbell Rogers sold 12,156 shares of Heartflow stock in a transaction that occurred on Friday, September 18th. The stock was sold at an average price of $50.15, for a total value of $609,623.40. Following the completion of the transaction, the insider directly owned 16,962 shares in the company, valued at $850,644.30. This trade represents a 41.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Campbell Rogers also recently made the following trade(s):

  • On Thursday, October 22nd, Campbell Rogers sold 12,157 shares of Heartflow stock. The shares were sold at an average price of $55.01, for a total value of $668,756.57.
  • On Tuesday, November 17th, Campbell Rogers sold 12,157 shares of Heartflow stock. The stock was sold at an average price of $46.39, for a total transaction of $563,963.23.
  • On Tuesday, November 17th, Campbell Rogers sold 24,188 shares of Heartflow stock. The stock was sold at an average price of $46.39, for a total transaction of $1,122,081.32.
  • On Thursday, October 22nd, Campbell Rogers sold 23,933 shares of Heartflow stock. The shares were sold at an average price of $55.01, for a total transaction of $1,316,554.33.
  • On Friday, September 18th, Campbell Rogers sold 19,682 shares of Heartflow stock. The shares were sold at an average price of $50.15, for a total transaction of $987,052.30.

Heartflow Price Performance

Shares of HTFL opened at $46.69 on Friday. Heartflow, Inc. has a twelve month low of $20.13 and a twelve month high of $60.65. The firm has a fifty day simple moving average of $51.76 and a two-hundred day simple moving average of $35.64.

Heartflow (NASDAQ:HTFL – Get Free Report) last released its quarterly earnings data on Thursday, November 12th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.15. The firm had revenue of $72.86 million for the quarter. Heartflow had a negative net margin of 33.11% and a negative return on equity of 20.53%. During the same quarter in the previous year, the firm posted ($0.27) EPS. On average, equities research analysts predict that Heartflow, Inc. will post -0.75 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. GAMMA Investing LLC grew its position in shares of Heartflow by 75.1% during the 3rd quarter. GAMMA Investing LLC now owns 641 shares of the company’s stock valued at $32,000 after acquiring an additional 275 shares during the period. IFP Advisors Inc increased its position in Heartflow by 844.7% in the third quarter. IFP Advisors Inc now owns 803 shares of the company’s stock worth $40,000 after buying an additional 718 shares in the last quarter. Allworth Financial LP raised its stake in shares of Heartflow by 56.5% in the third quarter. Allworth Financial LP now owns 828 shares of the company’s stock worth $41,000 after buying an additional 299 shares during the period. Integrated Wealth Concepts LLC bought a new position in shares of Heartflow in the second quarter worth about $53,000. Finally, Essential Partners LLC purchased a new position in shares of Heartflow during the 1st quarter valued at about $57,000.

Heartflow News Roundup

Investors following HTFL have been watching these news items:

  • Positive Sentiment: A report headline says Heartflow’s Q2 revenue beat consensus and the company raised its full-year guidance—potentially signaling stronger growth expectations. The provided article text offers few details on the results. Article: HeartFlow Q2 revenue and guidance
  • Negative Sentiment: Recent coverage flagged insider share sales, including a transaction reported at about $4.2 million. Other reports describe Campbell Rogers’ sales, some made under pre-arranged Rule 10b5-1 plans. Insider selling can unsettle investors, although planned sales do not necessarily signal a change in the insider’s view of the company. Article: Heartflow insider sale
  • Negative Sentiment: Put-option trading rose sharply, with 6,628 puts traded—about 558% above the reported average. This may reflect increased demand for downside protection or bearish bets, though options activity alone does not establish investors’ outlook.

Analyst Ratings Changes

Several analysts recently weighed in on HTFL shares. Benchmark reiterated a “buy” rating on shares of Heartflow in a report on Friday, August 14th. Robert W. Baird boosted their price target on shares of Heartflow from $56.00 to $68.00 and gave the company an “outperform” rating in a research report on Friday, November 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Heartflow in a research note on Wednesday, November 4th. Piper Sandler reissued an “overweight” rating and set a $64.00 price objective (up from $45.00) on shares of Heartflow in a research note on Tuesday, October 20th. Finally, JPMorgan Chase & Co. lifted their price objective on Heartflow from $35.00 to $45.00 and gave the company an “overweight” rating in a research note on Friday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $60.12.

Get Our Latest Stock Report on Heartflow

Heartflow Company Profile

(Get Free Report)

HeartFlow, Inc. is a medical technology company that develops noninvasive tools to help clinicians assess coronary artery disease. Its platform analyzes coronary CT angiography scans to create personalized models of a patient’s coronary arteries and provide information that can support diagnosis and treatment planning. The company’s offerings include HeartFlow FFR CT Analysis, which estimates blood flow and the effects of artery narrowing, and tools for assessing coronary plaque. The technology combines medical imaging with computational analysis and artificial intelligence, giving clinicians information without requiring an invasive procedure to measure blood flow.

Recommended Stories

Insider Buying and Selling by Quarter for Heartflow (NASDAQ:HTFL)

Receive News & Ratings for Heartflow Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heartflow and related companies with MarketBeat.com's FREE daily email newsletter.